Therapeutic transdermal drug innovation from 2000 to 2014: Current status and outlook

Jessica R. Walter, Shuai Xu*

*Corresponding author for this work

Research output: Contribution to journalShort surveypeer-review

17 Scopus citations

Abstract

The US Food and Drug Administration (FDA) approved the first transdermal drug over 35 years ago. Today, transdermal products represent a growing, multibillion dollar market. From 2000 to 2014, an average of 2.6 new transdermal drug were approved each year. However, only two of these approvals represented new molecular entities (NMEs). Furthermore, none of these approvals were designated for priority review by the FDA. Currently, transdermal drugs are limited in scope to fewer than 20 clinical indications. The past decade has seen significant safety, performance, and cost issues surrounding multiple transdermal drug products. As the field moves towards more complex drug-device combinations to overcome the natural barrier function of the skin, there will likely be more regulatory challenges, but also the potential for broader clinical scope.

Original languageEnglish (US)
Pages (from-to)1293-1299
Number of pages7
JournalDrug Discovery Today
Volume20
Issue number11
DOIs
StatePublished - Nov 1 2015

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Fingerprint Dive into the research topics of 'Therapeutic transdermal drug innovation from 2000 to 2014: Current status and outlook'. Together they form a unique fingerprint.

Cite this